Introduction
Abortion has been legal in Canada since 1969. 1 As many as 1 in 3 women will have an abortion, and until recently, surgical abortion (SA) was their only option. 2 In 2015, Health Canada approved the use of mifepristone/misoprostol (MIFE/ MISO) for medical abortion (MA), thus improving access to abortion services. 3 It is important to note that improved access to abortion services does not mean that more abortions occur. 1 In fact, abortion rates remained the same after the approval of medical abortion. The only change is that a larger proportion of abortions are provided through MA compared to a SA. For example, France has had access to MIFE since 1988, and MA is a more popular method of abortion than SA. 4 In 2017, Health Canada made several changes to make MIFE/MISO more accessible, such as extending its approved use from 49 days of pregnancy (7 weeks) to 63 days (9 weeks) and removing the training requirements to prescribe or dispense MIFE/MISO. 3 Many Canadian provinces are further increasing access by covering the cost of the medications under their respective provincial public drug plans. We have developed an infographic to help health care professionals support patients in the process of completing an MA. With access to MA on the rise, it is critical that pharmacists are aware of the role they play in educating and assessing patients who present with a prescription for MA. To develop the infographic, we performed a literature search using terms related to MA such as medical abortion guidelines, medical abortion in Canada, drug interactions AND medical abortion, pharmacists AND medical abortion and medical abortion trends in the PubMed, EMBASE and Google Scholar databases. We also searched for relevant grey literature such as government reports and local support groups using the Google search engine. This article will review what pharmacists need to know about MIFE/MISO.
What is medical abortion?
MA involves the use of 1 or more medication(s) to end a pregnancy. 1, 5 Although not approved, it can be used after 9 weeks, but it will be less effective. MIFE is a progesterone receptor modulator with antiprogesterone and antiglucocorticoid activity. 1, 5 It is taken first as a 200 mg tablet swallowed with a glass of water. 1, 5 MIFE begins the abortion by decreasing the levels of progesterone, which causes the uterine lining to detach, the uterus to become more contractile and the cervix to soften and dilate. 1, 5 MISO is taken 24 to 48 hours after mifepristone and comes packaged as four 200 mcg tablets that are usually taken buccally. 1, 5 Two tablets are placed in each cheek pouch to dissolve for 30 minutes (2 tablets in the left cheek and 2 tablets in the right cheek). 1, 5 Any remnants can then be swallowed with a glass of water. 1, 5 MISO is a synthetic prostaglandin that causes the cervix to soften and the uterus to contract, pushing out the contents of the pregnancy. 1, 5 MA can be prescribed and dispensed by physicians or nurse practitioners and dispensed by pharmacists. 3 Additional training or witnessed ingestion is no longer a requirement, as long as the practitioner is knowledgeable about MA.
3 PRACTiCeTOOL Therefore, patients can complete a MA in the comfort of their home, with the agreement of a follow-up visit with their prescriber after 7 to 14 days to confirm the abortion was successful.
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Contraindications to medical abortion
There are several conditions where MIFE/MISO is contraindicated, although some are relative. 1, 5 Pharmacists should confirm that no contraindications exist before dispensing MA. The Canadian Abortion Providers Support network provides useful checklists for prescribers and pharmacists. 6 Absolute contraindications include the following: the presence of an ectopic pregnancy, as MIFE/MISO will not work and surgery is more appropriate; chronic adrenal failure, as MIFE is a potent antiglucocorticoid that can decrease the action of cortisol replacement therapy; and inherited porphyria, as MIFE can increase the likelihood of an acute porphyria attack. 1, 5 Other absolute contraindications include uncontrolled asthma, a known allergy to the medications and patient uncertainty about having an abortion.
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The presence of an intrauterine device (IUD) is a relative contraindication, as the pregnancy has an increased chance of being ectopic. If an ectopic pregnancy is ruled out, the IUD must be removed before taking the MA medications. 1, 5 The need for long-term corticosteroid therapy is a relative contraindication, as effectiveness is reduced for 3 to 4 days after MIFE administration. 1, 5 Therefore, either a SA can be offered or the steroid therapy can be adjusted during MA, such as by increasing the dose for a week, although this will require close monitoring. 1, 5 Blood loss is routine with MA, so patients who have blood disorders, use anticoagulants or have severe anemia should use MA with caution. 1, 5 Patients with severe anemia (<95 mg/L) were excluded from studies in MA. 1, 5 Surgical abortion is the preferred method in many of these cases.
Drug interactions
Pharmacists play a significant role during MA dispensing, as they can easily identify drug interactions. Most patients will have painful cramps. Pharmacists can recommend nonsteroidal antiinflammatory drugs (NSAIDs) such as ibuprofen or naproxen. 1, 5 These are more effective than acetaminophen, and some patients may also wish to have a prescription for an opioid. 1 MISO can cause nausea, diarrhea, dizziness, fever and headaches usually within 2 to 4 hours of administration. 1, 5 Over-the-counter loperamide and dimenhydrinate can be helpful suggestions to combat these side effects. If patients vomit within 1 hour of taking MIFE, the pharmacist can contact the prescriber to request another dose to be taken with an antinausea medication like dimenhydrinate or ondansetron. 1, 5 By comparison, MISO is quickly absorbed. If the patient vomits when the MISO is still placed in the cheeks, she should be reassessed in 2 to 3 hours for onset of effect before taking a second dose. 1, 5 Pharmacists should also inquire about the plan for future contraception, as ovulation can occur within 8 days of MA. 1, 5 Patients can use condoms or barriers as soon as they feel ready to engage in intercourse. Oral contraceptive pills and progestin-only pills can be started when MISO is taken. 1, 5 An IUD can be inserted at the follow-up visit with the MA prescriber. 1, 5 Patients should seek urgent care when they are soaking 2 sanitary pads per hour for more than 2 hours, when they are passing tissue larger than a lemon for more than 2 hours and when the pain is unbearable and is not improving with medicine. 1, 5, 8 A fever of 38°C (100.4°F), nausea, vomiting, diarrhea, dizziness or weakness occurring more than 24 hours after MISO administration warrants emergency care.
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Practice tips
MA provides an additional opportunity for pharmacists to provide patient-centred care.
Here are some points to remember:
• Pharmacists do not need to complete a training or certification course to dispense MA.
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• MA is covered by most provincial public drug plans.
• MA administration does not need to be witnessed.
• MA is safe and effective. It is approved for use up to 63 days of pregnancy but can be used up to 70 days.
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• Keeping a list of contraindications can be helpful to review with every patient before dispensing MA.
• Consider adjusting steroid therapy by increasing the dose for 1 week after taking MISO and monitoring closely.
• Always assess for CYP3A4 drug interactions with MIFE and notify the patient on how MA will be affected. 1, 5 • Educate patients that heavy bleeding usually starts within 3 hours of misoprostol administration and light bleeding can last up to 2 weeks.
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• Patients should not use tampons, only sanitary pads, during MA. 1, 5 • Counsel patients about how to manage side effects with over-the-counter therapies such as NSAIDs, loperamide or dimenhydrinate.
• Educate patients on when they need another dose of medication if they vomit.
• Follow up with your patients to see how they are doing-having a strong support system can be helpful for patients and will strengthen the patient-pharmacist relationship.
Conclusion
Pharmacists are in a vital position when it comes to patient education and MA. 
